Nancy Lee, MD - ASTRO

More documents

Recommendations

Info

Mean Doses Right Parotid 19.80 Gy Right Parotid 19.80 Gy Left Parotid 24.94 Gy Oral Cavity 33.6 Gy
Page 1 and 2:
Head and Neck II: Oropharynx, Laryn
Page 4 and 5:
OROPHARYNX-Sites Base of tongue Sof
Page 6 and 7:
INCIDENCE OF LYMPH NODE METASTASES
Page 8 and 9:
CA. OF THE OROPHARYNX INCIDENCE OF
Page 10 and 11:
Oropharyngeal CA: Treatment Volume
Page 12 and 13:
RTOG 73-03 Oral Cavity And Orophary
Page 14 and 15: Surgery and Adjuvant RT vs. CCRT in
Page 16 and 17: Stage III/IV Head and Neck CA: Rand
Page 18 and 19: CA. OF THE TONSILLAR REGION LOCAL C
Page 20 and 21: CARCINOMA OF THE TONSIL LOCAL CONTR
Page 22 and 23: BASE OF TONGUE IMPLANTS Patient Sel
Page 24 and 25: BASE OF TONGUE IMPLANTS Dose to the
Page 26 and 27: Trans-Tasman Radiation Oncology PPo
Page 28 and 29: RTOG 90-03 PHASE III STUDY OF ALTER
Page 32 and 33: CB: 33% Late Grade 3-4 Toxicity
Page 34 and 35: • N=77 • IV=83% RTOG 99-14 Ang
Page 36 and 37: Gortec French Study DDenis i et t a
Page 38 and 39: French Trial: Oropharyngeal CA (D (
Page 40 and 41: There is also site-specific orophar
Page 42 and 43: Why shouldn’t we just treat all a
Page 44 and 45: Chemoradiotherapy: Late FT Dependen
Page 46 and 47: Chemoradiotherapy: Late FT Dependen
Page 48 and 49: An example of patient with late eff
Page 50 and 51: Historical RT Dose Escalation • I
Page 52 and 53: IMRT in the Treatment of Oropharyng
Page 54 and 55: Patients Population From 9/1998 to
Page 56 and 57: Local Control 3-year 94.4% 5-year 9
Page 58 and 59: Local Failure versus T-stage • T1
Page 60 and 61: Toxicities : Acute • Mucositis gr
Page 62 and 63: IMRT for oropharynx: available data
Page 69 and 70: IMRT vs sCo Conventional e to a RT
Page 71 and 72: Phase III trial (GORTEC 2004-01) St
Page 73 and 74: Conclusions • Excellent LRC is ac
Page 75 and 76: Larynx Cancer
Page 77 and 78: T1 Ca of the Glottis Radiotherapy D
Page 79 and 80: Local Control (%) LOCAL CONTROL OF
Page 81 and 82: Radiotherapy py Dose Fractionation
Page 83 and 84: Control (%) ( Local LOCAL CONTROL O
Page 85 and 86: Local Control (% %) LOCAL CONTROL F
Page 87 and 88: Randomized trial on RT fraction siz
Page 89 and 90: 2006 ASTRO S T R A T I F Y RTOG 95-
Page 91 and 92: S T R A T I F Y RTOG 91-11 Phase II
Page 93 and 94: RTOG 91-11 VA CCRT RT 2 year Laryng
Page 95 and 96: University of Chicago Stage IV of s
Page 97 and 98: T3-4 T3 4 Glottic/Supraglottic Node
Page 99 and 100: Stage T4 Carcinoma of the Glottis R
Page 101 and 102: T3 T3-T4, T4 N+ Glottic Surpaglotti
Page 103 and 104: VAH Laryngeal Carcinoma Study Laryn
Page 105 and 106: VAH Laryngeal Carcinoma Study Salva
Page 107 and 108: GETTEC Trial (J (J.M. M Richard Ri
Page 109 and 110: Vocal Cord Fixation • Retrospecti
Page 111 and 112: RTOG 91-11 Ph Phase III Trial T i l
Page 113 and 114: RTOG 91-11 Distant Metastases 5 yr*
Page 115 and 116:
T4a N+ N Glottic Surpaglottic TTrea
Page 117 and 118:
For T4a tumors: BID fractionation?
Page 119 and 120:
Concurrent Chemoradiation with Alte
Page 121 and 122:
Chemoradiotherapy py • In the set
Page 123 and 124:
EORTC 24891 LARYNX PRESERVATION FOR
Page 125 and 126:
Hypopharynx yp p y
show all

Nancy Lee, MD - ASTRO

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?